Moorthy S S Palanki

Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors.

Joel Renick, Kathy Barrett, Richard Soll, 2006, Bioorganic & medicinal chemistry letters.

Inhibitors of AP-1 and NF-kappa B mediated transcriptional activation: therapeutic potential in autoimmune diseases and structural diversity.

M. Palanki, Moorthy S S Palanki, 2002, Current medicinal chemistry.

Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays.

Hong Zhu, Feng Shi, Steven Hu, 2007, Bioorganic & medicinal chemistry letters.

Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration.

Hong Zhu, Steven Hu, Joel Renick, 2008, Journal of medicinal chemistry.